Autism - Drug Pipeline Analysis and Market Forecasts to 2016

Autism - Drug Pipeline Analysis and Market Forecasts to 2016 Summary GlobalData, the industry analysis specialist’s new report, “Autism - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global autism market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global autism market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global autism sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts. Scope The scope of the report includes: Annualized global autism market revenues data from 2001 to 2009, forecast forward for seven years to 2016. Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan. Pipeline analysis data, providing a split across different phases by mechanism of action being developed and emerging trends. Key classes of mechanism of action include 5-HT2A and D2 receptors antagonists, serotonin inhibitors, glutamate antagonists, antioxidants, cholinergic agents and immune response down regulators. Analysis of the current and future market competition in the global autism market. Key market players covered are Repligen Corporation, BioMarin Pharmaceuticals, and Neuropharm Group Plc. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for future market associated with autism. Reasons to buy The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to: Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the global autism market. Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global autism market in future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. What’s the next big thing in the global autism market landscape? - Identify, understand and capitalize.

Additional Information

Autism - Drug Pipeline Analysis and Market Forecasts to 2016

GlobalData, the industry analysis specialist, has released its latest research, “Autism - Drug Pipeline Analysis and Market Forecasts to 2016”, which provides key data, information and analysis on the autism market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecasts forward seven years to 2016. The research also includes market characterization, opportunities, the unmet needs, competitive assessments, the product profiles of major marketed products and promising drugs in the pipeline, an overview on discontinued projects, implications for future market competition, and the key players of the autism market.

The Autism Therapeutics Market is Forecast to Show Increased Growth until 2016

GlobalData has estimated the global autism therapeutics market to be valued at $331m in 2009. It is expected to grow to $649m with a compound annual growth rate (CAGR) of 11.5% by 2016. This growth is primarily attributed to the high increase in prevalence and also the fast increase in public awareness about the disease. Globally, the US remains the largest market for autism therapeutics, and was valued at $189m in 2009. It is forecast to grow at a CAGR of 12.9% over the next seven years to reach $442m by 2016.

Weak and Steady Increase in Disease Population to Boost the Present Market

The prevalence rate for autism globally was identified at 0.6% and this accounted for approximately 4.3 million people. Between 2009 and 2015 it is expected to increase from 4.3 million to seven million. The key factor attributed to this is the high incidence rate in new born in all parts of the world. Autism is highly prevalent in people aged one to eight. A significant increase in autism incidence has occurred over the past 10 years, especially in the new born population. From the above data it is clear that the number of autism (ASD) patients seeking treatment in the next five to 10 years would result in an increased usage of therapeutics drugs which in turn would drive the ASD therapeutics market.

Only Two Products Approved For Treatment

The global autism market is dependent on only two FDA approved drugs. Most patients are prescribed anti-depressant or anti-psychotic drugs to treat the symptoms related to autism. The patent expiry of marketed products such as Risperdal by 2008 allowed the entry of generic products at cheaper prices, reducing the market growth as well as the market size.

High Unmet Need in Terms of Safety Profile

The unmet need for autism therapeutics is estimated to be approximately $166m. Currently there is a significant market group that is likely to switch to new products with better efficacy and in particular, safety. As presented above, this unmet need is approximately 55% of the total market, which is valued at $331m. Therefore, the unmet need within the Autistic Disorder therapeutics market was estimated to be at least $182m in 2009. Based on our forecasts, this need is likely to grow to approximately $357m by 2016. There is unmet need in terms of safety, for which technologically innovative products will be required for value capture. The pipeline has limited emerging therapies that are likely to increase the growth of the present market.

Opportunity and Unmet Need in the Autism Market, 2010

Source: GlobalData